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ABSTRACT 
A-Type Lamins in Cell Cycle Regulation 
by 
Jaime Parman-Ryans 
Proteins of the nuclear lamina provide structural support to the nuclear envelope and 
participate in a variety of cellular functions, such as chromatin organization and transcriptional 
regulation.  One of these proteins, Lamin A (72kDa), is synthesized as a 74 kDa precursor 
protein, Prelamin A, which undergoes an unusual maturation pathway that requires two 
farnesylation-dependent endoproteolytic cleavages. The second cleavage is unique to lamin A 
in higher vertebrates and is specifically carried out by the endoprotease zmpste24. Although 
most previous studies have focused mainly on the function of mature Lamin A, recent evidence 
from our laboratory shows important biological functions for Prelamin A as well. Prelamin A 
concentration in proliferating cells is very low or undetectable. Conversely, during quiescence 
induced by mitogen withdrawal or contact inhibition, Prelamin A levels increase dramatically. 
These variations are directly regulated by changes in expression and enzymatic activity of 
zmpste24. The central hypothesis of this dissertation is that full-length farnesylated and 
carboxymethylated prelamin A (FC-PreA) antagonizes both proliferation and apoptosis, 
therefore playing a role in cellular quiescence/senescence.  To accomplish this goal, we studied 
the transcriptional regulation of zmpste24 and the interaction of FC-preA with proteins that 
participate in cell cycle control. 1) We identified and characterized a functional site for the E2F1 
transcription factor (involved in the control of cell cycle) in the proximal 5’ UTR region of 
zmpste24. 2) By using proximity-labeling and co-immunoprecipitation-mass spectrometry 
techniques, we identified a set of proteins that interact preferentially with L467R-Prelamin A 
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(uncleavable mutant) but not with mature Lamin A. Many of these proteins function to regulate 
progression through cell cycle.   
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CHAPTER 1 
INTRODUCTION 
The Nuclear Lamins 
There have been three different lamin genes identified in humans and other mammals:   
LMNA, LMNB1, and LMNB2.  The proteins encoded by these genes constitute the type V 
intermediate filament proteins that are separated into two classes, A-type lamins and B-type 
lamins (Goldman et al. 2002).  The A-type lamins:  A, A∆10, C, and C2 are spliced variants of the 
LMNA gene.  B-type lamins:  B1 and B2-B3 are coded for by two separate genes LMNB1 and 
LMNB2, respectively (Goldman et al. 2002). 
There are two major A-type lamins (lamins A and C) found in mammals, which are 
produced by alternate splicing of the LMNA gene, and these will be the focus of this work.  
Lamin A is synthesized first as a precursor prelamin A, and after post-translational modifications 
it becomes mature lamin A.  Both prelamin A and C have identical sequences for the first 566 
amino acids then lamin A has a 90- amino acid extension at its carboxyl terminus (Goldman et 
al. 2002).  Lamin C contains sequences from exons 1 to 10 and terminates with six amino acids 
that are not found in prelamin A (Lin and Worman 1993).  Prelamin A has sequences from two 
additional exons (exons 11 and 12) and terminates with 98 different residues (Lin and Worman 
1993).   
The nuclear lamins have the tripartite structure of intermediate filament proteins that 
consists of a highly α-helical central rod domain flanked by a short globular amino-terminal 
“head” domain and a longer carboxy-terminal “tail” domain (Parry et al. 1986).  The central rod 
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domain is made up of four sub-helical regions consisting of four heptad repeats designated as 
coil 1A, 1B, 2A, and 2B.  Those individual coils are separated from each other by three short 
linker segments, L1, L12, and L2 (Parry et al. 1986).  It appears that the head domain is 
unstructured, whereas the tail domain contains a highly conserved structural motif similar to a 
type S immunoglobulin fold (Ig-fold) (Dhe-Paganon et al. 2002; Krimm et al. 2002).  All lamins 
have a nuclear localization signal (NLS) that is located between the carboxy-terminal end of the 
central rod domain and the Ig-fold, that is required for transport into the nucleus (Figure 1) 
(Loewinger and Mckeon 1988). 
 
Figure 1: Structure of nuclear lamins. (A) Schematic drawing of prelamin polypeptide chain.  The 
structure consists of a central α-helical rod domain (red), the NLS (gray), Ig-fold (blue), and the C-
terminal –CAAX box (green).  (B) Schematic drawings of the C-terminal domains of mature lamins A, C, 
B1, and B2.  Adapted from (Dechat et al. 2008). 
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Lamin Processing Pathway 
The post-translational processing pathway of prelamin A was previously studied by Dr. 
Michael Sinensky’s laboratory, resulting in the description of a  unique set of post translational 
modifications prior to assembly into the nuclear lamina, out of the seven isoforms of lamin 
molecules (Sinensky et al. 1994).  Before full maturation, lamin A is synthesized as a 74kDa 
precursor, prelamin A (Figure 2).  Both lamin A and lamin B possess a canonical CAAX box (C= 
cysteine, A= aliphatic amino acid, X= serine, glutamine, methionine, or alanine) at the carboxyl- 
terminus of the molecule.  This CAAX box sequentially undergoes a series of three modifications 
in both lamin A and B (Sinensky et al. 1994).  The first step in processing is the addition of a 
farnesyl group to the cysteine of the CAAX box, accomplished by a farnesyl protein transferase.  
Next, the zinc metalloprotease zmpste24 performs an endoproteolytic cleavage termed 
“AAXing,” which removes the –AAX residues from the C-terminus of prelamin A.  Lastly, there is 
carboxymethylation of the newly exposed cysteine carboxyl group by means of an 
isoprenylcysteine methyl transferase (ICMT) (Sinensky et al. 1994)(Figure 2).  Subsequent 
modification to lamin A, includes a second endoproteolytic cleavage that removes the post-
AAX-processed 15 C-terminal amino acid residues (aa 647-661), which includes the farnesylated 
cysteine.  This second endoproteolytic cleavage is unique to lamin A in higher vertebrates and is 
specifically accomplished by the zinc metalloprotease zmpste24, which releases mature lamin A 
(Kilic et al. 1997).  Mature lamin A is found at the nuclear lamina and in the nuclear interior 
(Dobrzynska et al. 2016).  Since B type lamins do not undergo the second endoproteolytic 
cleavage by zmpste24 they are permanently farnesylated.  Also, Lamin C does not possess a 
CAAX box, and therefore is not farnesylated or methylated as previously described. 
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Figure 2: The maturation pathway of lamins.  1) Farnesyltransferase adds a farnesyl group to the 
cysteine of the –CAAX box of prelamin A, prelamin B1, and prelamin B2.  2) The last 3 residues (–AAX) 
are removed by an AAX endopeptidase 3) a carboxylmethyltransferase enzyme methylates the exposed 
terminal cysteine. 4) In prelamin A, Zmpste24/FACE1 cleaves the terminal 15 amino acids with the 
farnesyl groups attached.  This last cleavage step does not occur in B-type lamins, leaving them 
permanently farnesylated and carboxymethylated. Adapted from (Dechat et al. 2010). 
 
 
Lamins: Function 
The nuclear envelope is a double membrane structure that maintains the boundaries of 
the nucleus of a cell.  The inner membrane of the nuclear envelope is composed of a complex 
network of intermediate filament proteins known as the lamins (Aebi et al. 1986).  The lamins 
provide a structural network on the inner surface of the nuclear envelope to provide 
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attachment for various transmembrane proteins, organization of chromatin, transcription 
machinery, and distribution of nuclear pore complexes (Goldman et al. 2002; Dobrzynska et al. 
2016). 
A-type lamins are expressed mainly in highly differentiated cells and are soluble during the 
disassembly of the nuclear envelope that occurs during mitosis.  Whereas, B-type lamins are 
expressed in all cell types and remain associated with nuclear membrane vesicles during lamina 
depolymerization and breakdown of the nucleus during mitosis (Goldman et al. 2002).  Due to 
the various roles that A-type lamins play in the cellular functions, there is no wonder that they 
have been linked to various diseases referred to laminopathies; A-type lamins are also the main 
focus of this body of work. After the prelamin A has been fully processed into mature lamin A, 
multimeric polymerization with lamin B assists with the maintenance of the meshwork that 
lamin A forms on the inner layer of the nuclear membrane.  Lamin A protein polymers also 
permeate the cell nucleoplasm contributing to nuclear integrity, shape, nuclear organization, 
and nuclear stability  (Figure 3)(Goldman et al. 2002; Lammerding et al. 2004). Studies have 
shown that cells that are deficient in lamin A have a fragile nuclear membrane, therefore 
making them more subject to mechanical rupture or more likely to have nuclear membrane 
deformations such as blebbing and invaginations (Broers et al. 1997; Gruenbaum et al. 2000; 
Shumaker 2003; Bridger et al. 2007).  In addition, there have been some studies that propose 
that mutations in lamin A have resulted in cell death due to the rupture of the fragile nucleus, 
because of either impaired access to membrane binding receptor proteins, abnormal 
placement or stability of nuclear pores, or altered membrane transport; any of which would 
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compromise the structure and integrity of the nuclear membrane (Hutchison 2002; 
Lammerding et al. 2006). 
   
 
Figure 3: Interactions of lamins with inner nuclear membrane proteins. Lamin-binding proteins located 
in the INM, on chromatin, and in the nucleoplasm are thought to have mechanical and structural roles. 
The red lines are illustrations of lamins concentrated in the inner nuclear membrane and dispersed in 
the nucleoplasm (Adapted from Goldman et al. 2002). 
 
Lamin A also plays a critical role in the functional control of many cellular processes 
including transcription.  The spatiotemporal organization of lamin A allows them to participate 
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in maintaining cellular homeostasis.  A-type lamins have been reported to associate 
retinoblastoma protein (Rb) (Ozaki et al. 1994), sterol response element binding protein 1 
(SREPB1) (Lloyd et al. 2002), and zinc finger protein 239 (MOK2) (Dreuillet et al. 2002), thus 
affecting their expression levels.  This occurs by preventing ubiquitination and subsequent 
proteasomal degradation of the bound proteins.  It’s evident that if the structural integrity of 
the nucleus is compromised it could contribute to the dysfunction of these cellular processes; 
however, evidence has shown that these interactions are defective even in cases where the 
mutations in LMNA do not alter the structure of the nuclear envelope.  Hence, disorders that 
have been related to lamin A dysfunction could not be attributed solely to nuclear integrity, but 
instead, to the control of the functions that depend on interactions with lamin A, independent 
of the structural maintenance of the nucleus (Gruenbaum et al. 2000; Hutchison 2002; 
Hutchison and Worman 2004; Lammerding et al. 2006; Bridger et al. 2007).   
Several studies have shown that A-type lamins contribute to regulation of cell 
proliferation and tissue homeostasis (Chen et al. 2009; Naetar and Foisner 2009).  A-type lamins 
are soluble during the disassembly of the nuclear envelope during mitosis (Gerace and Blobel 
1980; Lutz et al. 1992; Goldman et al. 2002); however, unprocessed prelamin A cannot 
assemble into the lamina (Holtz et al. 1989; Lutz et al. 1992).  These findings are consistent with 
the hypothesis that the carboxyl terminal tail of prelamin A is inhibitory for assembly of lamin A 
into the lamina and that the farnesylation-dependent cleavage of prelamin A allows assembly 
lamin A into the lamina to continue.  Unpublished data from our lab showed that the 2KDa, 
15aa peptide released in the processing of lamin A is rapidly degraded in cells. Microinjection of 
the same 2kDa prelamin A peptide (chemically synthesized) to cultured fibroblasts produced no 
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apparent effects.  With these negative findings, there is a possibility that farnesylated and 
carboxymethylated prelamin A (FC-prelamin A) has a biological effect.  Studies relating to the 
laminopathies have given some new insight into the possible function for FC-prelamin A (Davies 
et al. 2011). 
ZmpSte24 Crystal Structure 
ZmpSte24 is an inner nuclear membrane zinc metalloprotease that is essential to the 
maturation of lamin A.  Zmpste24 is also known as farnesylated-protein converting enzyme-1 
(FACE-1, Hs Ste24) and its crystal structure has recently been described by Quigley et al.2013.  
The 3.4 angstrom (Å) resolution structure was determined from protein purified in two 
different detergent-lipid systems.  This gave two independent crystal packing arrangements 
each with four copies of the structure in the asymmetric unit.  The 3.4 Å structure was solved to 
help understand how zmpste24 cleaves prelamin A and how mutations in zmpste24 cause 
laminopathies (Quigley et al. 2013).   
Zmpste24 has a seven transmembrane α-helical barrel structure that encloses a rather 
large chamber, and spans the membrane (Quigley et al. 2013)(Figure 4, A and B).  The seven 
transmembrane helices (TMH) are packed in an antiparallel α-helical bundle, with the zinc 
metalloprotease fold inserted between TMH5 and TMH6.  The nucleoplasmic side of the 
membrane is sealed by an M48 zinc metalloprotease domain, while the endoplasmic reticulum 
lumenal face of the membrane, and is sealed by three lumenal α-helices (LH), LH1, LH2, and 
TMH7A.  There is access to the chamber from the nucleoplasm and the membrane by four 
fenestrations (Quigley et al. 2013)(Figure 4C).  Simulations using molecular dynamics of 
zmpste24 in lipid bilayers, showed that the structure is stable when the chamber is filled with 
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water.  The interior of the chamber has a mixed polar-nonpolar character with a prominent 
charged patch between TMH1 and TMH7 and three hydrophobic patches on the adjacent wall 
between TMH4 and TMH5, around the extensive S1’ and S2’ substrate specificity sites, and on 
the endoplasmic reticulum lumenal face of the chamber (Quigley et al. 2013)(Figure 4C).  A 
synthetic peptide substrate that matches the C-terminus of prelamin A was used to show that 
purified zmpste24 has the expected proteolytic activity at the second cleavage site (Quigley et 
al. 2013)(Figure 4D).  These findings were consistent in that zmpste24 has a longer substrate 
with the farnesyl group attached to allow for proper alignment of the peptide in the active site.  
To confirm this model they used shorter peptides, less than 15 residues, that were cleaved 
incorrectly at sites adjacent to the expected cleavage sites (Quigley et al. 2013)(Figure 4, D to 
F). 
The catalytic zinc ion is found on the nucleoplasmic side of the membrane at the apex of 
the chamber (Quigley et al. 2013)(Figure 5A).  The zinc ion is coordinated by His335 and His339 
from the HEXXH zinc metalloprotease motif (H335 ELGH in zmpste24) and Glu415 from TMH7 
(Quigley et al. 2013)(Figure 5A).  Glu336 from the HEXXH motif is predicted to be the catalytic 
residue, that activates a catalytic water molecule to attack the substrate peptide bond  (Quigley 
et al. 2013).  Structural alignments predict that Asn265 and His459 would stabilize the transition 
state during catalysis (Quigley et al. 2013).   
A potential substrate-binding site was inferred from a 3.8 Å structure of a complex 
between zmpste24 and Cys-Ser-Ile-Met (CSIM) tetrapeptide from the C-terminus of prelamin A 
(Quigley et al. 2013)(Figure 5, B and C).  The peptide-binding groove lies between the Zn2+ ion 
and strand β3 of the metalloprotease β sheet and potentially interacts with highly conserved 
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residues, such as Asn265 on β3, His459 on a loop between metalloprotease helices (MHs) MH5 
and MH6, and Arg465 on MH6 (Quigley et al. 2013).  The deep pocket that encompasses both 
the S1’ and S2’ subsites (Figure 5B), is lined by highly conserved hydrophobic residues 
contributed by MH3, MH4, MH6 (Quigley et al. 2013).  Such hydrophobic pockets could dictate 
the specificity of substrate binding for residues adjacent to the cleavage sites (Quigley et al. 
2013).   
 
Figure 4: Structure and activity of the zmpste24 zinc metalloprotease.  (A) Cartoon representation of 
structure, viewed in the plane of the membrane. The structure is colored from blue to red from N to C-
terminus. The catalytic zinc and its coordinating residues are highlighted in magenta. Horizontal lines 
indicate the approximate extent of the lipid bilayer as observed in MD simulations. The nucleoplasmic-
cytoplasmic and ER lumen sides of the membrane are indicated. (B) Topology diagram of the 
arrangement of TMHs, colored as in (A). The metalloprotease fold is highlighted in pale blue. (C) Cut-
away molecular surface representations highlighting the intramembrane chamber. The location of a 
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fenestration between TMH5 and TMH6 in the chamber wall is marked with an asterisk. (D) ZmpSte24 is 
thought to cleave the C-terminus of prelamin A at the two sites indicated by black arrows.  (E) Cleavage 
was assessed using synthetic peptides derived from the C-terminus of prelamin A with a mass 
spectrometric assay.  Two peptides (26-amino acid peptide including fCys661 and 11-amino acid peptide) 
probing the second cleavage site were cleaved between Tyr646 and Leu647, as expected.  Additional 
cleavages were observed for the shorter peptide between Leu647 and Leu648 and Gly649.  (F) Two 9–amino 
acid peptides, with and without an fCys661 were unexpectedly cleaved between Ser662 and Ile663. Green 
and blue triangles indicate expected and additional cleavages, with light colors for low-abundance 
reactions. Used with permission from Andrew Quigley et al. Science 2013; 339:1604-1607. 
Figure 5: Active site of zmpste24. (A) Detailed view of the catalytic zinc-binding site. The active site is 
viewed looking from the ER lumen side of the membrane toward the nucleoplasmic end of the 
intramembrane chamber. Side chains are shown for highly conserved residues involved in zinc 
coordination, substrate binding, and catalysis. Molecular surface representation (B) and view of the 
active site (C) with a model of the prelamin A C-terminus bound in the active site, viewed from inside 
the chamber. Peptide carbons are colored green. (B) Is colored as for Fig. 4C and (C) as for (A). The 
fenestration, which could act as the entry and exit route for the prelamin A C-terminus, is marked with 
an asterisk, and the potential exit route for the SIM product is shown with a black triangle. The expected 
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cleavage site is indicated by a blue arrow in (C). Used with permission from Andrew Quigley et al. 
Science 2013; 339:1604-1607. 
The prelamin A substrate could enter the chamber via one of the four fenestrations in 
the chamber wall (Quigley et al. 2013)(Figure 4C).  Since the chamber is too small to 
accommodate the whole 74-kD prelamin A, the unstructured C-terminus would insert into 
chamber, entering and exiting by the same route (Quigley et al. 2013).  The most likely entry 
route is the fenestration between TMH5, TMH6, and the β hairpin connecting β3 and β4 
(Quigley et al. 2013)(Figure 4C, 5B and 6A).  
It connects the chamber with the nucleoplasm and the inner leaflet of the inner nuclear 
membrane, which are the locations of the protein and farnesyl moieties of the substrate 
(Quigley et al. 2013)(Figure 6, A and B).  By using this entry route it would allow for correct 
alignment of the prelamin A C-terminus with the active site of zmpste24 for cleavage of the SIM 
sequence (Quigley et al. 2013).  After cleavage, the tripeptide product would be able to exit via 
a fenestration between TMHs 1 and 2  (Quigley et al. 2013)(Figure 5B).  The partially processed 
prelamin A C-terminus would then completely leave the chamber or project into the membrane 
through one of the fenestrations, which allows for carboxymethylation by ICMT, before 
prelamin A reenters the chamber (Quigley et al. 2013).  The second cleavage site is 15 residues 
from the farnesylated Cys661 at the C terminus.  There is sufficient space in the chamber for the 
additional residues and possibly a binding site for the farnesyl group at the endoplasmic 
reticulum lumen end of the chamber, which aligns the substrate for the second cleavage 
(Quigley et al. 2013)(Figure 6B).  The C-terminus of lamin A would then leave the chamber as 
soluble nucleoplasmic lamin A (Quigley et al. 2013).  Quigley et al. also showed the location of 
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the major laminopathy-causing mutations in zmpste24 as related to its structure (Figure 7) 
(Quigley et al. 2013).  The crystal structures of zmpste24 provide a structural basis for protease-
associated laminopathies; however, there is still much to be learned about this protein.   
 
Figure 6:  Proposed substrate entry route for the C-terminus of prelamin A and scheme for the 
reactions performed by zmpste24.  (A) The fenestration between TMH5 and TMH6, below the β3-β4 
hairpin is likely to be the entry route for the substrate. It provides a direct route into the active site, such 
that the C-terminus of prelamin A would be aligned with the peptide binding site identified in our 
protein-peptide complex. The 3D modelled peptide is shown with the carbon atoms in green. (B) 
Scheme for the reactions performed by zmpste24. The C-terminus of prelamin A is colored as in Fig. 3D, 
with the farnesyl group shown in pale green and the residues preceding the cleavage sites highlighted. 
Steps in the reaction scheme are numbered. Used with permission from Andrew Quigley et al. Science 
2013; 339:1604-1607. 
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Figure 7: Laminopathy-causing mutations in zmpste24.  Six mutations in zmpste24 lead to reduced 
enzyme activity and varying severity of disease. (A) Five of these mutations (N265S, L438F, L462R, 
W340R, and P248L, red spheres) lie in the zinc metalloprotease domain (gold) and one (L94P) is found in 
the ER lumen end of the chamber. The model for the bound CSIM tetrapeptide is shown in green. (B) 
Three mutations (N265S, L438F, and L462R) cluster around the substrate-binding or active site, and two 
MAD-B mutation sites (W340R and P248L) are located near the β3-β4 hairpin adjacent to the proposed 
substrate entry fenestration. (C) The L94P mutation lies at the elbow between TMH2 and LH1. These 
two helices, together with TMH3 pack together to form a fenestration, adjacent to Phe133, which links 
the chamber to the lipid bilayer. Mutated residues are shown as red sticks with semi-transparent 
molecular surfaces (B and C). Used with permission from Andrew Quigley et al. Science 2013; 339:1604-
1607. 
Laminopathies 
Laminopathies are diseases that result from mutations in the lamins or the genes that 
encode the proteins that are responsible for lamin processing.  The laminopathies are 
connected because they are all linked to very rare premature aging syndromes (Worman and 
Bonne 2007).  Mutations in the LMNA gene are responsible for at least a dozen different 
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disorders, although there have also been a couple of disorders associated with the genes that 
encode for the B-type lamins (Worman et al. 2010).   Laminopathies are classified into three 
different categories; those that affect striated muscle; adipose tissue; and diseases that involve 
peripheral neuropathy (Broers et al. 2004).  
The first laminopathy identified was Emery-Dreifuss muscular dystrophy (EDMD), which 
occurs in two forms and is inherited in either an X-linked or autosomal dominant or recessive 
manner (Bione et al. 1994; Worman et al. 2009).  The first manifestation of symptoms begins in 
the first decade of life with contractures of the elbows, ankles, and posterior neck.  During the 
second decade of life, there is a slow progressive muscle weakening and wasting.  The most 
significant of the EDMD symptoms is cardiomyopathy, which occurs in all cases and presents 
initially as a block in atrioventricular conduction followed by left ventricular dilation and 
congestive heart failure (Bione et al. 1994; Worman et al. 2009).  
Dunnigan-type familial partial lipodystrophies (FPLD and mandibular acral dysplasia 
(MAD) are disorders that involve peripheral loss of adipose tissue, which leads to severe insulin 
resistance (Broers et al. 2004; Worman et al. 2009).  At birth, patients have normal fat 
distribution, but at puberty they begin to lose subcutaneous adipose tissue in the extremities, 
which give them the appearance of a muscular physique; this is accompanied by an increase in 
adipose tissue in the face and neck (Broers et al. 2004; Worman et al. 2009).  Additional 
phenotypes for MAD are typical of premature aging and include hypoplastic mandibles with 
severe dental crowding, short stature, and alopecia (Cao and Hegele 2000; Shackleton et al. 
2000; Novelli et al. 2002).     
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Charcot Marie Tooth disorder type 2 (CMT2) is caused by a LMNA mutation that affects 
peripheral nerves.  Patients affected by CMT2 have muscle weakness and wasting of the lower 
limb muscles (Worman et al. 2009).  The velocity of motor nerve conduction is normal or 
slightly reduced due to axonal neuropathy (Worman et al. 2009).  CMT2 patients will also 
sometimes exhibit muscular dystrophy and/or cardiomyopathy (Benedetti et al. 2005; Walter et 
al. 2005).  
Hutchinson-Gilford progeria syndrome (HGPS) is a rare, autosomal dominant, fatal, 
progressive premature aging syndrome (Olive et al. 2010).  Most HGPS cases are caused by a 
single de novo nucleotide substitution at position 1824 (C→T) in exon 11 of the LMNA gene.  
This mutation is also denoted as G608G because the encoded amino acid for codon 608 
remains glycine (Eriksson et al. 2003; De Sandre-Giovannoli et al. 2003; Varga et al. 2006).  This 
mutation creates a cryptic splice site, which deletes 50 amino acids (LA∆50) (Eriksson et al. 
2003; Corrigan et al. 2005; Shumaker et al. 2006; Dechat et al. 2010).  In this deletion the 
second endoproteolytic cleavage site, in the prelamin A processing pathway, that is recognized 
by zmpste24 is deleted, thus preventing the release of mature lamin A.   The resulting mRNA 
transcript codes for a mutant lamin A protein called progerin (Shumaker et al. 2006).  Death of 
HGPS patients occurs at a mean age of 13 years because of myocardial infarction or stroke due 
to atherosclerosis (Olive et al. 2010).  Currently, there is no cure for patients with HGPS.  
A loss of zmpste24 leading to the accumulation of farnesylated prelamin A has been 
associated with the lethal disorder Restrictive Dermopathy (RD) (Worman et al. 2009).  It was 
originally believed that RD was caused by a heterozygous mutation of zmpste24 in association 
with a mutation in another gene, but ultimately it has been shown that RD results from 
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homozygous loss of zmpste24 (Navarro et al. 2005).  RD is characterized by tight translucent 
skin, slow growth during gestation, severe contractures of the joints, craniofacial abnormalities, 
epidermal hyperkeratosis, and death following birth due to pulmonary hypoplasia and 
restricted movement (Navarro et al. 2005).  MAD has also been described as a milder form of 
RD, due to similarities associated with the accumulation of prelamin A (Agarwal et al. 2003).    
Thus far, there have only been two disorders associated with the genes that encode for 
the B-type lamins.  The first is an LMNB1 duplication with adult onset autosomal dominant 
leukodystrophy, which is a very slow and progressive fatal disorder characterized by pyramidal 
and cerebellar dysfunction along with symmetrical demyelination of the central nervous system 
(CNS) (Padiath et al. 2006; Worman and Bonne 2007).  The other disease  that has been linked 
to B-type lamins is a mostly sporadic acquired form of progressive lipodystrophy, called 
Barraquer- Simons syndrome (Worman and Bonne 2007).   There is little data in how mutations 
in the genes encoding B-type lamins cause disease (Worman and Bonne 2007; Worman et al. 
2009)      
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Aims of This Study 
A long standing goal of our laboratory has been to understand the physiological 
significance of the prelamin A processing pathway.  Studies on cultured fibroblasts from 
patients with HGPS and RD have provided clues as to the function of this processing pathway: 
expression of farnesylated and carboxymethylated prelamin A results in a gain of function and 
that function manifests itself in replicating cells in chromatin re-organization and a concomitant 
cellular senescence.  Other literature on prelamin A and cell proliferation also indicates a role 
for its accumulation in quiescence.  We propose that zmpste24 is down regulated in quiescent 
cells, resulting in the accumulation of FC-prelamin A and that down-regulation of zmpste24 
serves to produce and/or maintain the quiescent state.  We also propose that persistent 
accumulation of FC-prelamin A, in response to the down-regulation of zmpste24 or by other 
means, facilitates senescence by chromatin reorganization.  We want to better understand the 
normal functions of FC-prelamin A, in particular how it relates to cellular quiescence and 
senescence.  To accomplish this goal, we attempted to characterize the promoter and 
transcription factors regulating the expression of zmpste24 as well as identify and characterize 
specific FC-prelamin A interacting partners.  
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CHAPTER 2 
MATERIALS AND METHODS 
Mammalian cell culture 
Various cell lines were used in these studies including: HeLa cells, BJ fibroblasts, WI-38 
fibroblasts, HEK293T cells, LMNA cells, and L647R cells.  All cell lines were maintained in a 
humidified incubator at 37°C with 5% or 10% CO2, per cell requirements.   
HeLa cells, BJ fibroblasts, WI-38 fibroblasts, and HEK293T cells were all cultured using 
standard Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented with 10 % FBS and 1% 
Penicillin/ Streptomycin antibiotics.  Rheoswitch® cells expressing various lamin A protein 
chimeras were cultured in DMEM, supplemented with 10% heat inactivated FBS, 2.5 ml 
Hygromycin, 4 ml of G418 antibiotics, and 1% Penicillin/ Streptomycin.   
Transient Transfection 
Two different methods were used to introduce plasmid DNA into mammalian cells.  
MegaTran 1.0 (Origene Technologies, Rockville, MD) is a non-lipid polymer-based reagent that 
provides high efficiency and low toxicity for transfected cells.  Typically cells were plated in 35 
mm or 60 mm plates for transfection and grown until cell density was approximately 60-70% 
confluent.  Depending on the plate size used, 2-8 µg of DNA was transfected.  Plasmids were 
diluted in 100 µl of DMEM without antibiotics and vortexed gently.  MegaTran 1.0 reagent was 
added to the diluted DNA at a 3:1 ratio, then vortexed gently for 10 seconds and incubated at 
room temperature for ten minutes.  Culture media was removed and the cells were washed 
with PBS, and refed with fresh culture media and the MegaTran 1.0/DNA mixture was added to 
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the culture plates.  Generally the MegaTran 1.0/DNA mixture represented ~10% of the total 
volume of the culture media.  The plates were gently rocked to ensure even distribution of the 
complexes and then incubated at 37°C for 24-48 hours.  If cells were incubated for 48 hours, 
the media was replaced with fresh complete growth media 24 hours after the transfection.   
Magnetofection™ Polymag reagent (OzBiosciences, France) was also used for some of 
the transient transfections.  The Magnetofection™ Polymag reagent uses microscopic magnetic 
particles that adhere to the DNA.  The DNA/magnetic particle suspension is added to adherent 
cells at 60-90% confluency at the time of transfection.  The culture plates are then placed on a 
magnet for approximately 20 minutes to force the microscopic magnetic/DNA coated particles 
through the plasma membranes of the cells.   
DNA Digestion with Restriction Enzymes    
Plasmid DNA and insert DNA of interest were digested with corresponding restriction 
enzymes according to manufacturer’s protocol.  Typically, 5 µg of DNA was digested using 5 
units of restriction enzyme in 20-50 µl of 1X digestion buffer for one hour at 37°C.   
DNA Gel Electrophoresis  
The results of restriction digests were checked by DNA gel electrophoresis using 0.6% 
agarose gels made with 1X Tris-borate EDTA buffer (TBE) ran at 100V for 90 minutes.  Ethidium 
bromide was added to the gel to a final concentration of 5 µg/ml for visualization of the DNA 
fragments.  DNA fragments were observed using an ultraviolet (UV) light box.   
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DNA Purification from Agarose  
Following DNA gel electrophoresis, regions of the gel containing fragments of interest 
were excised from the gel and weighed.  The DNA was extracted from the gel using a QIAquick 
Gel Extraction kit according to the manufacturer’s instructions (Qiagen).  Briefly, the gel slice 
was dissolved in solubilization buffer by incubating at 50°C for 10 minutes with vortexing every 
2-3 minutes.  Isopropanol was then added and the sample was transferred to a QIAquick spin 
column (Qiagen) and centrifuged for one minute.  The column was washed twice using wash 
buffer and the DNA was eluted using 50 µl of elution buffer and centrifuging for one minute.  
The concentration of DNA was determined by spectral analysis using the NanoDrop™ 2000 
(Thermo Fischer Scientific).   
DNA Ligation 
After restriction digest the plasmid vector of interest was treated with calf intestinal 
alkaline phosphatase (CIP) to dephosphorylate the 5’-ends of the DNA to maintain linearization.  
For the ligations, T4 DNA Ligase (Promega) was used according to the manufacturer’s protocol.  
Using a 3:1 molar ratio of vector: insert DNA all ligation reactions were carried out overnight at 
4°C.  After ligation the new constructs were transformed into bacterial cells using either DH5α™ 
competent cells (Invitrogen/Life Technologies) or SURE® competent cells (Stratagene/Agilent 
Technologies).    
DNA Transformation 
Transformation of plasmid DNA into cells was completed using one of two types of cells; 
DH5α™ Competent Cells (Invitrogen/Life Technologies) or SURE® Competent Cells 
(Stratagene/Agilent Technologies).  For transformations using the DH5α™ Competent Cells, 
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after cells were thawed on ice; 5 ng of plasmid DNA was added to 50 µl aliquots and mixed 
gently, incubated on ice for 30 minutes, and then heat shocked for 20 seconds in a 42°C water 
bath without shaking.  Cells were placed back on ice for two minutes and 950 µl of pre-warmed 
SOC media (Super optimal broth with catabolite repression) was added to each tube.  Tubes 
were incubated at 37°C for one hour with shaking at 225 rpm to promote growth.  After 
incubation 50-100 µl of each transformation was plated on selective plates containing 100 
µg/ml of ampicillin and incubated overnight at 37°C.  pUC19 control DNA was used as a positive 
control for the transformation, which was provided by the company. 
For transformations using SURE® Competent Cells a 14 ml Falcon polypropylene tube 
was pre-chilled on ice and 100 µl of cells were added to each tube along with 1.7 µl of β-
mercaptoethanol.   The tubes were swirled gently to mix and incubated on ice for ten minutes 
with swirling every two minutes.  Next, 20 ng of plasmid DNA was added the incubation 
continued for 30 minutes.  The cells were then heat shocked in a 42°C water bath for 45 
seconds, placed back on ice for two minutes before the addition of 0.9 ml of pre-warmed SOC 
media.  The cells were then incubated at 37°C for one hour with shaking at 225-250 rpm.  100 µl 
of the transformation mixture was spread on selective LB agar plates containing 100 µg/ml of 
ampicillin and incubated overnight at 37°C.  For all transformations, pUC18 plasmid provided 
with the competent cells, was used as a positive control.       
DNA Isolation 
For plasmid DNA purification, Wizard® Plus Midipreps DNA Purification System 
(Promega) was used.  After transformation, isolated colonies were selected and added to 100 
ml of LB broth containing 100 µg/ml of ampicillin and incubated overnight at 37°C with shaking 
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at 225-250 rpm.  Cultures were pelleted by centrifugation at 10,000 x g for ten minutes at 4°C.  
The supernatant was removed and excess liquid was allowed to drain off.  Cell pellets were 
completely resuspended in 3 ml of cell resuspension solution and 3 ml of cell lysis solution was 
added and mixed by inversion.  Neutralization solution (3ml) was added and mixed by inversion 
then centrifuged at 14,000 x g for 15 minutes at 4°C.  The supernatant was carefully removed 
and transferred into a new centrifuge tube.  Wizard® Midipreps DNA Purification Resin was 
added to the DNA solution and mixed.  The DNA/resin mixture was transferred to Midicolumn 
and a vacuum was applied to pull the mixture into the Midicolumn.  The column was washed 
with 40% isopropanol and column wash solution using a vacuum to pull the solution through 
the Midicolumn.  The DNA was eluted using 300µl of nuclease free water that had been 
preheated to 70°C.  DNA concentration was determined by spectral analysis using the 
NanoDrop™ 2000 (Thermo Fischer Scientific).  DNA was stored at -20°C until use.   
Site-directed Mutagenesis 
The (His)6-WT zmpste24 in pBacpak8 was used as the template for site-directed 
mutagenesis using the Stratagene QuickChange® Lightning Site Directed Mutagenesis Kit 
(Stratagene/Agilent Technologies).  Six mutants were generated using this template: ∆HEXXH, 
H335A, Y379Stop, L290Stop, P230Stop, and C109Stop.  According to the manufacturer’s 
instructions for the QuickChange PCR reaction, primers were used to insert the mutant 
sequences into the WT and are listed below; anti-sense primers were also designed for each 
mutant to correspond with the reverse complement for each one.  The mutants were 
transformed into bacterial cells after PCR was complete, colonies selected, grown overnight and 
DNA was isolated as described previously.    
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∆HEXXH 5’-CTCGCTGTACTAGGCTGGAAGTTGGGACATAC-3’ 
H335A  5’-CTCGCTGTACTAGGCGCCGAATGGGGCACTGG-3’ 
Y379Stop 5’-TTTGCTGCATTTGGTTTTTAGGATAGCCAACCCACTC-3’ 
L290Stop 5’-ACTAGAAGAGTACTCTGTATAGAACAAAGACATCCAGGAGG-3’ 
P230Stop 5’-TGACAAATTCACACCTCTGTAGGAGGGAAAGCTTAAAGAAG-3’ 
C109Stop 5’-GACTTTCTGGACGGTTCTAGGGTTATGCTGGCTTTGG-3’ 
Immunofluorescence 
Cells were grown on glass coverslips overnight.  After washing with PBS, cells were fixed 
in freshly prepared 4% paraformaldehyde in PBS, pH 7.3.  Cells were permeabilized with 0.2% 
Triton X-100 in PBS for five minutes on ice, washed with PBS and blocked with 10% BSA in PBS 
on ice for 5 minutes.  Coverslips were incubated for one hour at room temperature with 
primary antibody.  Then cells were washed and incubated with the secondary antibody that was 
fluorophore conjugated at room temperature for one hour.  Cells were washed three times 
with PBS and mounted to glass slides using an anti-fade mounting solution containing DAPI 
(Prolong).  Images were acquired by digital deconvolution of 10-slice stacks using a Nikon 
Diaphot 200 microscope equipped with a Retiga2000 cooled CCD digital camera, Oncor Z-drive 
and Oncor Image Software.   
Base Release Assay 
Cells (1 x 107) were labeled overnight with [methyl- 3H] methionine (100 μCi/ml) (the 3H-
methyl group will be incorporated into S-adenosyl methionine (The methyl donor on the 
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carboxymethylation step) and will also label all the remaining methionines in proteins. Prelamin 
A is isolated by immunoprecipitation with prelamin A specific antibody (α-PreA) followed by 
separation on SDS-PAGE. Lamin B is immunoprecipitated with commercially available antibody 
(Santa Cruz) as a control for a 100% carboxymethylation. Proteins were visualized by 
fluorography and the corresponding bands for proteins of interest are cut from the dried gel, 
placed into 0.5 ml microfuge tubes, and then rehydrated with 100 μl of distilled water.  200 μl 
of 1 M NaOH is added to the tubes and incubated at 37° for 24h in capped parafilm-sealed 
scintillation vials containing 2.5 ml of scintillation fluid.  The base releasable counts (tritiated 
methanol) are trapped in the scintillation fluid.  The gel slices are recovered and dissolved in 
Perchloric acid-H2O2 and counted.  These counts represent the non-releasable counts.  The ratio 
of counts released to counts retained are normalized relative to the number of methionines in 
the protein and expressed as a fraction of the normalized result for lamin B. 
ZmpSte24 Endoprotease Assay 
ZmpSte24 activity was assayed using nuclei from HeLa cells as the source of enzyme 
activity as described by Kilic et al. 1997, with the exception that we used the hexapeptide 
RSY*LLG, where Y* is a 14C-labeled tyrosine, as the substrate.  Cells were collected by 
trypsinization and washed twice with ice-cold PBS.  Cell pellets were resuspended to a final 
density of 4 x 108 cells/ml in a lysis buffer (0.01 M Tris-HCl, pH 7.0, 0.01 M NaCl, 3 mM MgCl2, 
0.4% Nonidet P-40) (Kilic et al. 1997).  Nuclei were washed two more times in the same buffer, 
isolated and then pelleted by centrifugation in a Beckman J-14 rotor for ten minutes at 365 x g.  
The nuclei were resuspended in the same buffer without the Nonidet P-40 and assayed.  The 
Qubit® Protein Assay Kit was used to obtain the protein concentration.  14C-labeled peptide 
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(RSY*LLG final concentration of 5µM) was used to initiate the endoprotease reaction, leaving 
the nuclear preparation in a final volume of 200 µl in 10 mM MES, pH 6.0.  The reaction was run 
for various periods of time at 37°C, then stopped by the addition of 5 µl of glacial acetic acid 
and chilled on ice for ten minutes.  The reaction mix was cleared by centrifugation at 2,000 rpm 
for ten minutes using an Eppendorf centrifuge.  The supernatant was collected and lyophilized, 
the RSY* residue was resuspended in 25 µl of water and isolated by reverse phase thin layer 
chromatography (TLC) (Analtech, Inc. Newark, DE).  TLC plates were developed in 10% 
acetonitrile in water, and the spots were visualized by autoradiography.  A synthetic, 14C-RSY* 
peptide standard was run on each plate to aid in the identification of the expected product.  
The amount of labeled RSY formed in the assay was determined by scraping the appropriate 
spots into tubes and quantified by scintillation counting.  
Cell Proliferation Assay Using [3H]-Thymidine 
DNA synthesis was examined by pulse labeling for 30min with [3H]-Thymidine at various 
time points.  Cells were washed two times with cold PBS, collected by scraping into 1 ml of PBS, 
homogenized by sonication, and a 0.2 ml aliquot was combined with 1 ml of cold trichloroacetic 
acid (TCA).  The suspension was filtered to remove all insoluble material and washed with cold 
TCA.  The amount of radioactivity that was incorporated was measured by scintillation 
counting.  
Cell Proliferation Assay Using BrdU 
Cells were seeded in triplicate at 4 x 103 cells/well in a 96-well plate or on glass 
coverslips and incubated overnight.  Genostat inducer at concentrations of 0 nM, 200 nM, 400 
nM, 600 nM, and 800 nM were used to treat cells for 48 hours, DMSO was used as a control.  
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Plates were incubated for four hours in the presence of 10 µM BrdU (5-Bromo-2’-deoxyuridine), 
then incubated for one hour with a monoclonal anti-BrdU antibody (1/100), and washed three 
times with TBST.  Cells were then incubated with an anti-mouse IgG FITC conjugated secondary 
antibody for an hour.  For the 96-well plates a plate reader was used to measure absorbance at 
450 nm.  Coverslips were mounted in an anti-fade mounting solution containing DAPI (Prolong).  
Samples were analyzed by fluorescence microscopy, and the number of BrdU positive cells 
were counted in twenty 40X fields per treatment/time point.  The amount of BrdU that was 
incorporated into the cells was quantified, thus indicating the amount of cell proliferation 
taking place.      
Induction of Quiescence 
HeLa, WI-38 and BJ cells used in serum starvation experiments were maintained in 
normal growth medium containing 10% FBS until time for use, then washed with PBS.  The 
medium was then replaced with medium containing 0.5% FBS.  Cells were collected at the 
various time points as stated in the results after the serum removal.  Contact inhibition studies 
used cells that were plated at 2.5 x 103 cells/cm2 or at 1 x 105 cells/cm2 and grown for the times 
indicated in the results. 
Co-immunoprecipitation - Mass Spectrophotometry Analysis 
Twenty-five micrograms of affinity-purified rabbit anti-prelamin A (Sinensky et al. 1994), 
monoclonal anti-Lamin A/C (clone 4C11, Sigma-Aldrich) or control rabbit antibodies were 
covalently linked to 50 μl of packed Affiprep protein A beads (Bio-Rad Laboratories), pre-eluted 
with glycine (Moritz et al. 1998), incubated with 700-1000 μL of fresh whole cell extract at 4°C 
for 1 h, washed five times with lysis buffer I (50 mM HEPES at pH 7.5, 100 mM KCl, 1 mM MgCl2, 
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1 mM EGTA, 10% glycerol, 0.05% NP-40, 1 mM DTT, protease inhibitors) and once with lysis 
buffer without NP-40, and eluted by heating at 50°C in 50 μL of Novex® Tris-Glycine SDS Sample 
Buffer (Thermo Fisher). 
SDS-PAGE was used to separate and purify proteins, which were stained using Colloidal 
Coomassie Brilliant Blue or by silver staining to visualize the proteins so that the appropriate 
bands could be excised.  Isolated proteins were then treated with iodoacetamide and digested 
with trypsin.  Ms. Gawinowic at the Protein Chemistry Core Facility at Columbia University 
performed the MADLI-TOF with PerSeptive Voyager DE-RP mass spectrometer. 
Preparation of Cell Lysates 
Transfected cells were washed twice with room temperature PBS, trypsinized, collected 
and centrifuged for 3 minutes at 1500 rpm. The cell pellet was washed twice with ice-cold PBS 
and centrifuged again to re-pellet the cells.  The pellet was resuspended in 0.6 ml of 0.4% SDS 
RIPA buffer with 1X Halt Protease and Phosphatase Inhibitor Cocktail.  Cells were transferred to 
a new tube and incubated for 30 minutes on ice and vortexed every 10 minutes for 30 seconds.  
Samples were centrifuged at 10,000 x g for ten minutes at 4°C, and the supernatant was 
transferred to a new tube.  If a cell pellet was still visible, additional lysis buffer, sonication and 
centrifugation steps were performed until the pellet was completely solubilized.  Lysates were 
stored at -20°C until use and protein concentrations were measured using the Qubit® Protein 
Assay.     
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Protein Assay 
Protein assays were performed using the Qubit® Fluorometer (Invitrogen/Life 
Technologies).  Thin walled, clear, 0.5 ml PCR tubes that were provided in the kit were used for 
preparation of the standards and samples.  The Qubit® working solution was prepared by 
diluting the Qubit® Protein reagent 1:200 in Qubit® Protein buffer; 200µl was prepared for each 
sample including standards.  Each standard included 190 µl of Qubit® working solution and 10 
µl of standard, then mixed by vortexing for 2-3 seconds.  Qubit® working solution was added to 
the samples so that the final volume was 200 µl, then mixed by vortexing for 2-3 seconds.  All 
tubes were incubated at room temperature for 15 minutes.  Standards and samples were read 
using the Qubit® 2.0 Fluorometer by inserting each tube individually into the sample chamber.  
Results were displayed on the instrument screen and recorded.  
Protein Electrophoresis and Transfer 
One dimensional SDS-PAGE was performed to separate the proteins under reducing 
conditions on a 4-12% gradient Bis-Tris NuPAGE precast slab gel from Invitrogen (Carlsbad, CA).  
Electrophoresis was performed at 200 volts for 45 minutes to an hour using the Novex Surelock 
System from Invitrogen.   Broad range pre-stained protein markers from Invitrogen were used 
to estimate the relative molecular masses of the proteins.  After electrophoresis, proteins were 
transferred to a polyvinylidene difluoride (PVDF) membrane using a dry electroblotter called 
the iBlot (Invitrogen/Life Technologies, Carlsbad, CA).  The transfer was approximately seven 
minutes and was performed according the manufacturer’s instructions. 
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Western Blot 
Following transfer to PVDF, membranes were blocked for 1 hour at room temperature 
or overnight at 4°C in 5% nonfat milk in tris-buffered saline containing 0.1% Tween 20 (1X-
TBST). Membranes were washed four times for five minutes each using 1X-TBST and probed 
with the indicated primary antibodies using the dilutions specified by the manufacturer.  
Antibodies were diluted in 1X-TBST containing 5% nonfat milk for 1 hour a room temperature 
or overnight at 4°C.  Membranes were washed as previously described and incubated with the 
indicated secondary antibody conjugated to a horseradish peroxidase (HRP) (Santa Cruz) at 
room temperature for 1 hour.  After incubation with the secondary antibody, membranes were 
washed and antibody–bound proteins were detected using enhanced chemiluminescence 
reagent (ECL) from Pierce (Rockford, IL).  ECL was added to cover the membrane and incubated 
for five minutes at room temperature.  Excess ECL was removed and membranes were covered 
with a plastic film.  ECL signal was visualized using the Fuji Film Imager LAS-4000. 
Dual-Luciferase® Reporter Assay 
HEK293T cells were plated at 700,000 cells/60 mm culture dish, grown overnight, and 
transfected as previously described using the MegaTran 1.0 reagent.  The vectors used for the 
transfections were pGL4 Luciferase Reporter Vectors (Promega, Madison, WI), pGL4.27 
[luc2P/minP/Hygro] and pGL4.77 [hRlucP/Hygro].  Vector pGL4.27 [luc2P/minP/Hygro] 
contained the sequence of interest (e.g. ccgggcccggaactcgg).  For some experiments, co-
transfections were also performed using an E2F1 expression vector under the control of a CMV 
promoter (Invitrogen).  48 hours after transfection growth medium was removed and 
transfected cells were washed with phosphate buffered saline (PBS).  PBS was completely 
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removed and 500µl of 1X passive lysis buffer (PLB) was added to each well of the culture plate.  
The culture plate was placed on an orbital shaker with gentle shaking for 15 minutes at room 
temperature and cells were scraped into a microfuge tube.  Luciferase Assay Reagent II (LARII) 
and Stop & Glo® were prepared according to manufacturer’s instructions (Promega, Madison, 
WI).  20µl of cell lysate suspended in PLB was dispensed into a 96 well plate, followed by 
sequential auto-injection of LARII and Stop & Glo® Reagents.  Plates were read using a 
Molecular Devices L Max Microplate Reader, Luminometer, with Softmax Pro software.  The 
luminometer was programmed to perform a 2-second premeasurement delay, followed by a 
10-second measurement period for each reporter assay.    
Chromatin Immunoprecipitation (ChIP) qPCR or RT2 Endpoint PCR. 
ChIP was accomplished using the EpiTect® Chip qPCR assay for human zmpste24 
(Qiagen).  Cells expressing uncleavable prelamin A (L647R) and cells expressing mature lamin A 
were plated and grown overnight to 70-85% confluency in a 10 cm culture dish.  Medium was 
removed from cells and 10 ml of fresh fixing buffer consisting of 1% formaldehyde in PBS was 
added and incubated at 37°C for 10 minutes, fixing the cells in formaldehyde cross-links the 
DNA sequences of interest to prelamin A.  1.1 ml of Stop buffer (Qiagen) was added to each 
plate and swirled to mix.  Plates were incubated for 5 minutes at room temperature.  The Stop 
buffer was removed and cells were washed with 9 ml of ice-cold 1X PBS two times.   
Cell Harvesting.  Cells were harvested, by scraping, in 1.5 ml of ice-cold harvesting 
buffer, containing 3 ml of PBS and 15 µl of protease inhibitor cocktail (PIC).  The supernatant 
was collected in a new tube and placed on ice.  Collected supernatant was centrifuged at 800 x 
g for 10 minutes at 4°C.  The harvesting and centrifugation steps were repeated twice to ensure 
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that all cells were collected.  Pelleted cells were resuspended in 100 µl of lysis buffer (Qiagen) 
containing PIC, then incubated on ice for 10-15 minutes with mixing every 5 minutes.  Cell 
lysate was sonicated to shear the DNA.  The probe was inserted to a 2-3 mm depth in the 
lysate.  The sonicator was set on Power: 0.5 W; Time: 2 seconds ON/ 15 seconds OFF; Total 
time: 16 seconds (8 times per round); 3 rounds.  Lysates were mixed by pipetting up-and-down 
after each round to prevent precipitation before the next round of sonication.  The lysate was 
centrifuged at 14,000 x g for 10 minutes at 4°C to pellet the debris.  Supernatant was carefully 
removed and transferred to a new tube and labeled as ChIP Ready Chromatin.   
Pre-Clear and Immunoprecipitation.  For each sample 900 µl of IP Buffer A (Qiagen) 
containing 7.5 µl of PIC was added to 100 µl of ChIP Ready Chromatin, mixed and placed on ice.  
50 µl of Protein A beads (Qiagen) were added and incubated for 50 minutes at 4°C with 
rotation.  Samples were centrifuged at 4000 x g for 1 minute at 4°C, then placed in ice for 1 
minute to allow the Protein A beads to settle.  After the beads settled, supernatant was 
carefully removed and placed in a new ice-cold 5 ml tube.  A 1 ml aliquot of the supernatant 
was removed for a negative control, positive control, and the antibody fraction.  The antibodies 
prelamin A, mature lamin and H2A.Z were used.  Fractions were incubated with their respective 
antibodies overnight at 4°C with rotation.  For the immunoprecipitation, 60 µl of Protein A 
beads (Qiagen) were added to each fraction and incubated at 4°C for one hour with rotation, 
then centrifuged at 4000 x g for one minute at 4°C.  Tubes were placed on ice for one minute to 
allow the Protein A beads to settle, then supernatant was removed and discarded.  The bead 
pellet, containing the Protein A-antibody/chromatin complex was resuspended and washed in 1 
ml each of the four cold wash buffers, supplied in the kit according the manufacturer’s 
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instructions (Qiagen).  After each wash, samples were centrifuged briefly for one minute and 
supernatant was carefully removed. 
DNA Isolation and Purification.  To elute the DNA, 30 µl of elution buffer (Qiagen) 
containing 2 µl of ChIP-Grade Proteinase K was added directly to each sample and incubated 
with shaking at 500 rpm at 45°C for 30 minutes.  100 µl of DNA extraction beads (Qiagen) was 
added to each sample and vortexed for 10 seconds, then incubated with shaking at 95°C for 10 
minutes, and centrifuged at 14,000 x g for one minute at room temperature.  Without 
disturbing the pellet, the supernatant was removed and placed in a new tube.  Another 100 µl 
of elution buffer was added to each sample, vortexed for 20 seconds, and centrifuged as 
before.  The supernatant was once again removed and added to the previous tube for a total of 
200 µl. 
DNA was purified using the DNA Spin Columns provided (Qiagen).  To each 200 µl 
sample, 400 µl of column binding buffer (Qiagen) was added followed by mixing.  The samples 
were transferred to individual DNA spin columns, in a 2 ml collection tube, and centrifuged at 
11,000 x g for one minute at room temperature.  The flow-through material was discarded, spin 
column was washed with 600 µl of Column wash buffer (Qiagen), then centrifuged again.  The 
flow-through material was once again discarded, the DNA spin column was centrifuged at 
11,000 x g for 2 minutes to remove any residual wash buffer.  The DNA spin column was placed 
in a clean elution tube, and 100 µl of Elution Buffer (Qiagen) was added to the center of the 
column membrane and incubated for 1 minute at room temperature.  Spin columns were 
centrifuged for 1 minute at 11,000 x g at room temperature.  The elution step was repeated 
with another 100 µl of elution buffer, to yield a final volume of 200 µl for each ChIP sample.   
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After purification of DNA, the samples were analyzed by Endpoint PCR using RT2 
Endpoint PCR Kit (SABiociences) or taken to the Molecular Biology Core Facility at James H. 
Quillen College of Medicine for quantitative analysis by qPCR.           
Cell Lines for Proximity Labeling Experiments 
To create the Lamin-biotin ligase fusion proteins, biotin ligase was sub-cloned from a 
pcDNA3.1 MCS-BirA (R118G)-HA plasmid donated by Kyle Roux from University of South 
Dakota. The biotin ligase (BL) fragment was excised and ligated in frame into pNEBR-X1, pNEBR-
X1-GFP-lamin A, and pNEBR-X1-GFP-L647Rprelamin A (all created by Christina Bridges in our 
laboratory) to create BL-GFP-Lamin chimeras. The pNEBR-X1 plasmids are part of the 
Rheoswitch® inducible expression system from New England Biolabs. The BL plasmids were 
purified and constructs confirmed by DNA sequencing.  
Stable Rheoswitch® cell lines expressing BL-GFP-Lamin A and BL-GFP- L674Rprelamin A 
were created by transfecting Rheoswitch® 3T3 cells using Mirus TransIT 3T3 reagent. After 24 h, 
cells were incubated with 800ug/ml G418 and 200ug/ml Hygromycin for two weeks and cell 
colonies of resistant cells were selected, expanded and checked for inducible expression in 
response to RSL1 (GenoStat™ New England Biolabs and VWR). 
Proximity Labeling Protocol  
Rheoswitch® cells harboring the BL-Lamin constructs were incubated for 24-48 h in the 
presence of 800nM GenoStat and 50 M biotin. After three PBS washes, 1-2 x 107 cells were 
lysed by sonication in 0.4% SDS RIPA buffer containing complete protease/phosphatase 
inhibitor cocktail. After initial sonication, Triton X-100 was added to a final concentration of 2% 
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and centrifuged at 15,000 x g.  Biotinylated proteins were isolated from the supernatant by 
incubation with Streptavidin-Dynabeads (Invitrogen) for 16 h, beads were collected using a 
magnetic tube rack and washed three times in 2% SDS for 5 min.  Beads were washed once with 
wash buffer I (0.1% deoxycholate, 1% Triton X-100, 500 mM NaCl, 1 mM EDTA, and 50 mM 
Hepes, pH 7.5), once with wash buffer II (250 mM LiCl, 0.5% NP-40, 0.5% deoxycholate, 1 mM 
EDTA, and 10 mM Tris, pH 8.1) and twice with wash buffer III (50 mM Tris, pH 7.4, and 50 mM 
NaCl).  An aliquot of the sample (10%) was reserved for Western blot analysis. Bound proteins 
were eluted from the beads with Novex® Tris-Glycine SDS Sample Buffer (Thermo Fisher) 
saturated with biotin and incubated for 10 min at 90°C. Eluted proteins were reduced, alkylated 
and subjected to SDS-PAGE. Protein-containing lanes were cut into 5 mm pieces and sent to AB 
Sciex (Farmington, CT) or Columbia University core facility for tryptic in-gel digestion and 
identification by LC-MS/MS mass spectrometry. Raw data were converted into mzdata.xml 
using MassHunter Qualitative Analysis software (Agilent Technologies) and database search 
was performed using MASCOT 3.2 (MatrixScience) and human IPI database.  
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CHAPTER 3 
RESULTS 
Unsuccessful Attempts to Prove a Two-active Site Hypothesis for Zmpste24 
Prior results from our laboratory had indicated that the prelamin A endoprotease 
responsible for the second endoproteolytic cleavage was a chymotrypsin like enzyme with a 
serine active site (Kilic et al. 1999); rather than a Zn+2 dependent metalloprotease (Schmidt et 
al. 2000).  This conclusion was based on the use of protease inhibitors to inhibit zmpste24 
activity in both the “AAXing” and the second cleavage reactions in the conversion of prelamin A 
to lamin A. In more recent studies from our laboratory, site directed mutagenesis was used to 
delete the HEXXH motif in zmpste24 (Corrigan 2005).  These results showed that the HEXXH 
motif deletion in zmpste24 abolishes its ability to perform the first cleavage (AAXing) activity 
but not second cleavage activity. Furthermore, zmpste24 was tagged by incubation with a 
fluorescent analogue of the suicide inhibitor TPCK, (5(6)-carboxyfluoresceinyl-L- phenylalanine 
chloromethylketone or FFCK), which specifically inhibits chymotrypsin-like serine proteases by 
the same mechanism as TPCK, namely by alkylation of the active-site histidine. Purification of 
fluorescently tagged fragments and MALDI-TOF analysis demonstrated that zmpste24 was 
indeed covalently modified by FFCK suggesting the presence of a chymotrypsin-like active site 
somewhere in zmpste24 structure (Corrigan 2005). 
In order to narrow down a region containing the active site, or at least a residue 
associated with the active site, Corrigan used site-directed mutagenesis to introduce premature 
stop codons at predetermined locations in zmpste24.  He then expressed and purified the 
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truncated zmpste24s in E. coli, and measured their activity in an AAXing, and second cleavage 
reactions in an assay using a prelamin A carboxy terminal fragment as a substrate (Corrigan et 
al. 2005; Corrigan 2005). His findings identified one truncation, Y379Stop, which abolishes the 
AAXing activity, while leaving the second cleavage activity intact (Corrigan 2005).  
Patients with MAD or RD have a mutation 1085insT in exon 9 that causes a frameshift 
and a premature termination codon resulting in the truncated protein, Phe361fsX379.  This is 
similar to our Y379Stop mutant (Agarwal et al. 2003; Navarro et al. 2004; Navarro et al. 2005).  
The loss of AAXing activity correlates with the results observed by Agarwal et al., which show 
that the Phe361fsX379 mutant form of zmpste24 could not complement a Ste24 deletion 
mutant of yeast that is defective in the processing of its prenylated yeast substrate, a-factor 
(Agarwal et al. 2003).  The results from this endoproteolytic assay on prelamin A, show the 
MAD and RD phenotype observed in patients is more than likely a result of the inability of 
zmpste24 to properly AAX the prelamin substrate.  Additionally, in this truncated form of 
zmpste24 the HEXXH motif, located at residues 335-339, is retained, thus suggesting the 
possibility that another sequence C-terminal to the HEXXH motif is also needed for AAXing to 
occur.  Alternatively, it is possible that the residues located C-terminal to the Y379STOP 
truncation are needed for proper substrate recognition and/or proper folding of zmpste24.   
Based on all of these results, we decided to test the ability of four truncated forms of 
zmpste24 to rescue the wild-type proliferation phenotype of fibroblasts from RD patients or 
Zmpste24-KO mice. These fibroblasts develop premature senescence in culture.  To this end, 
premature stop codons were inserted into the predicted cytosolic or luminal loop regions 
located outside the boundaries of the transmembrane regions (Figure 8).  This placement 
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allowed for proper transmembrane insertion of predicted transmembrane helices located N-
terminal to the stop codon. 
 
 
Figure 8. Location of Stop codons in zmpste24 truncations.  Above is the predicted transmembrane 
topology map for zmpste24, as predicted by the TMHMM Server v. 2.0 server 
(http://cbs.dtu.dk/services/TMHMM/).  Shown is the positioning of the four amino acids that were 
mutated into stop codons (C109, P230, L290, and Y379). 
 
Truncated zmpste24 constructs were created as described in Materials and Methods, 
and expressed in fibroblasts from zmpste24 knock out mice donated by Dr. Carlos Lopez-Otín 
and Ignacio Varela from Oviedo University, Spain.  While in the process of characterizing the 
Y379Stop 5’-TTTGCTGCATTTGGTTTTTAGGATAGCCAACCCACTC-3’ 
L290Stop 5’-ACTAGAAGAGTACTCTGTATAGAACAAAGACATCCAGGAGG-3’ 
P230Stop 5’-TGACAAATTCACACCTCTGTAGGAGGGAAAGCTTAAAGAAG-3’ 
C109Stop 5’-GACTTTCTGGACGGTTCTAGGGTTATGCTGGCTTTGG-3’ 
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created cell lines, Quigley et al. solved the 3.4Å structure of human zmpste24 to understand 
how this enzyme cleaves prelamin A and how various mutations in zmpste24 cause 
laminopathies.  They were able to confirm and show the seven transmembrane α-helical barrel 
structure of zmpste24 and that it is surrounding a large, water-filled, intramembrane chamber, 
and capped by a zinc metalloprotease domain with the catalytic site facing into the chamber 
(Quigley et al. 2013).  They used a synthetic peptide substrate that matched the C-terminus of 
prelamin A (Ser636 to fCys661), to show that purified zmpste24 did perform the proteolysis at the 
second cleavage site (Figure 4D).  This group also showed that the catalytic site of zmpste24 is 
found at the apex of the chamber on the nucleoplasmic side of the membrane (Figure 
4A)(Quigley et al. 2013).  The zinc ion is coordinated by His335 and His339 from the HEXXH zinc 
metalloprotease motif (H335ELGH in zmpste24) and Glu415 from TMH7 (Figure 5A) (Quigley et al. 
2013).  The observed second cleavage accomplished by zmpste24 between Tyr646 and Leu647, 
was executed as expected and previously described (Barrowman et al. 2012; Quigley et al. 
2013).   
With the construction of this zmpste24 model there was no evidence of a second active 
site mediated by a serine protease type of activity.  Therefore, disproving our “two site” 
hypothesis.  The second endoproteolytic cleavage of prelamin A is indeed accomplished by the 
zinc metalloprotease zmpste24. Explanation for the results obtained with serine-protease 
suicide inhibitors followed by mass spectrometry was later provided by several groups 
(Grabarek et al. 2002)(Grabarek and Darzynkiewicz 2002).   
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Expression of Type A Lamins in Quiescence and Senescence 
It has been extensively studied that actively proliferating cells including some cancer cell 
lines (Lin and Worman 1997), particularly embryonal carcinomas (Lebel et al. 1987; Stewart and 
Burke 1987; Mattia et al. 1992), and various hematopoietic stem cell types (Rober et al. 1990; 
Broers et al. 1997; Pierce et al. 1999), do not express lamin A/C.  Additionally, several cell types 
that are terminally differentiated into a non-proliferative state (e.g. some classes of 
neurons)(Broers et al. 1997; Pierce et al. 1999) also lack lamin A/C expression.  This provides a 
link between cells that can exhibit conditional proliferation and lamin A/C expression, which 
opens the possibility that a product of the LMNA gene expression may be involved in the 
maintenance of cells in a non-proliferative state like quiescence or senescence.  Quiescence is 
defined as cells having the ability to re-enter the cell cycle; whereas, senescence is the loss of 
the ability to re-enter the cell cycle. 
One of the goals of this study is to examine the mechanisms by which prelamin A 
accumulation affects cellular quiescence/senescence. Is prelamin A accumulation a byproduct 
or an mediator of quiescence? Does a persistent buildup of prelamin A lead to senescence? 
What are the molecular mechanisms? 
Early work by Dr. Michael Sinensky and later by Christina Bridges in our laboratory showed 
that mevalonate and serum deprivation leads to accumulation of prelamin A and growth arrest 
in HeLa cells, F9 cells and human diploid fibroblasts (Sinensky et al. 1994; Bridges 2012).  Here 
we show that incubation of NIH 3T3 cells in 0.5% FBS for 48hrs leads to accumulation of prelamin 
A in the nucleoplasm (Figure 9A).  On the other hand, cells that were actively proliferating and 
56 
 
maintained in full serum and analyzed under the same conditions, did not show any detectable 
levels of prelamin A (Figure 9A lower panels).  
 
Figure 9: Accumulation of prelamin A upon serum starvation. A) Immunofluorescence using a prelamin 
A C-terminus specific antibody in proliferating or serum starved NIH 3T3 fibroblasts after 48 hours. 
Exposure for fluorescence photos was 5 seconds (Top) and 1 minute (Bottom). B) Western blot, using a 
lamin A/C antibody and lysates from NIH 3T3 cells grown in medium with 10% FBS, 0.5% FBS and 0.5% 
FBS for 48h and re-fed with 10% FBS for 24h. Lovastatin was used as a control to increase the levels of 
prelamin A. Upper band: Prelamin A; Middle band: Mature Lamin A; Lower band: Lamin C. 
 
Cell lysates were also collected after serum starvation and analyzed by Western blot 
(Figure 9B). The results show an increase in the accumulation of prelamin A in serum deprived 
cells. Also note the complete absence of detectable prelamin A when cells are grown in normal 
medium (10% FBS) and after serum deprived cells were re-fed with of 10% FBS containing 
medium for 24 h.  Similar results were observed with serum-starved BJ fibroblasts, HeLa cells, 
and contact inhibited NIH 3T3 cells (data not shown).  
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Given the nature of the maturation pathway of lamin A, it was important to know 
whether the C-terminus of the prelamin A that accumulates in serum starved cells has been 
properly processed. Mammalian cells possess a second enzyme, Ras-converting enzyme 1 
(Rce1) that is capable of performing the endopeptidase activity of step 1 in the prelamin A 
processing pathway (Winter-Vann and Casey 2005).  The Rce1 enzyme has been demonstrated 
to be active in step 1 endoprotease processing of both Ras proteins (Winter-Vann and Casey 
2005) and lamin B (Maske et al. 2003) raising the possibility that CAAX box processing, including 
carboxymethylation can occur even in the absence of zmpste24. 
Figure 10: Prelamin A that accumulates in quiescent BJ cells is farnesylated and carboxymethylated. A) 
Mass spectral analysis of prelamin A from serum starved BJ cells. B) Carboxymethylation of prelamin A 
accumulating in serum starved BJ human diploid fibroblasts (incorporation of alkali-releasable counts 
from ([3H]-methyl) methionine). Lamin B was used as a positive control. 
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To assess degree of maturation of the prelamin A that accumulates in serum starved 
cells we used MALDI-TOF mass spectrometry to detect the signature mass peak for farnesylated 
and carboxymethylated prelamin A (Figure 10A). The C-terminal tryptic fragment at mass 
996.23 was present in all samples from serum-starved BJ fibroblasts indicating that the 
prelamin A that accumulates has undergone the farnesylation, AAXing and carboxymethylation 
steps and is ready for the step 2 endoproteolysis by zmpste24. Since farnesylated peptides 
sometimes are under-represented on MALDI-TOF runs, a more quantitative measure of the 
accumulated farnesylated and carboxymethylated prelamin A can be obtained from the base-
release assay (Figure 10B). In this assay, fully mature lamin A should not be labelled by ([3H]-
methyl) from methionine since its C-terminal 2KDa peptide is lost after the step 2 
endoproteolysis. On the other hand, lamin B should be fully labelled and can be used as a 
positive control. In the case of prelamin A, the base release assay provides a measure of the 
extent of accumulation of farnesylated and carboxymethylated protein. So, the vast majority of 
prelamin A that accumulates in quiescent cells is farnesylated and carboxymethylated (Figure 
10B) as compared to the permanently farnesylated and carboxymethylated lamin B. 
Since FC-prelamin A is a farnesylated protein, some general consideration of the 
properties of prenylated, particularly, farnesylated proteins is warranted.  Prenyl modifications, 
including farnesylation, can be viewed as a mechanism for mediating protein-protein 
interactions, as opposed to simple binding to lipid bilayers. Recent reviews of this subject 
(Rusinol and Sinensky 2006; Davies et al. 2011) maintain the same perspective. Indeed, 
farnesylation and carboxymethylation are best viewed as weak membrane anchors which 
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provide a mechanism for membrane association that is reversible upon binding by other 
proteins that recognize these  
 Figure 11: Zmpste24 expression in serum-deprived WI38 cells. Northern blot of zmpste24. A 32P-
labeled zmpste24 cDNA probe was hybridized to RNA collected from WI38 cells grown in 0.5% FBS 
medium. β–Actin was used as loading control. 
 
structural elements and a second site on the farnesylated protein. In the case of FC-prelamin A, 
a specific heterodimeric partner was identified some years ago by the Worman lab (Barton and 
Worman 1999). We have now extended this number to nine proteins that interact with 
prelamin A but not lamin A; described later in this document (Table 1). 
The nature of the prelamin A that accumulates in quiescence makes the second 
endoproteolytic step by zmpste24 the most desirable step to study. Previous data from our 
laboratory (Bridges, 2011) showed that zmpste24 protein levels and activity decrease when 
HeLa cells are serum deprived.  Zmpste24 activity decreases in parallel to the rate of cellular 
proliferation, as shown by thymidine incorporation into DNA, thus indicating that prelamin A 
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accumulation in quiescence is due to zmpste24 inhibition or reduced expression.  When serum 
was returned to the cultures, an increase in cell proliferation as well as zmpste24 activity was 
observed (Bridges, 2011).  
Here we show the levels of zmpSte24 mRNA measured in actively proliferating WI38 
cells in full serum and after serum starvation to induce quiescence.  There was a drastic 
decrease in the level of mRNA transcript over a two-day period (Figure 11) suggesting a 
transcriptional regulation mechanism for intracellular levels of FC-prelamin A.   
To determine whether the down-regulation of zmpste24 in quiescent cells has 
physiological significance, we examined, as a model, WI-38 fibroblasts rendered quiescent by 
growth to confluence.  Cells were plated at low and high density so that the effect of expression 
of zmpste24 on quiescence produced by contact inhibition could be compared with DNA 
synthesis in proliferating and non-proliferating cells.  
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The results in Figure 12 show that overexpression of zmpste24 enhances the 
proliferation of confluent cells to essentially the same level as non-confluent cells. 
 
Figure 12: Effect of zmpSte24 overexpression on proliferation of contact inhibited human diploid 
fibroblasts.  WI-38 fibroblasts were plated at low (2500 cells/cm2) or high (25000 cells/cm2) density and 
transfected with an empty vector or a plasmid that expresses zmpSte24 under the control of a CMV 
promoter (Origene- pCMV6-XL5).  Untransfected cells plated at low density (red circles), untransfected 
cells plated at high density (red triangles), zmpSte24 transfected cells plated at low density (blue circles), 
and zmpSte24 transfected cells plated at high density (blue triangles).  
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Characterization of Promoter and Transcription Factors That Regulate ZmpSte24 Expression 
Computer analysis (Genomatrix or Promo) of the 5’ flanking sequence of the zmpSte24 
gene (Accession # NM_005857) is consistent with several E2F1 binding sites with varied degrees 
of probability. This was accomplished by focusing on the sequence CCGGGCCCGGAACTCGG 
located about 100 bp (bp -124 to -108) upstream of the zmpste24 transcription start site, using 
a dual luciferase assay (Promega, Madison, WI) to determine if zmpSte24 is transcriptionally 
regulated by E2F1.   
The putative E2F1 binding site sequence was ligated into minimal promoter pGL4 
Luciferase Reporter Vector (Promega, Madison, WI), that were used expressed Firefly and 
Renilla luciferase (pGL 4.27 and pGL 4.77).  These distinct luciferases have dissimilar enzyme 
structures and substrate requirements which make it possible to selectively discriminate 
between their respective bioluminescent reactions.  This provides a convenient means of 
correcting for transfection efficiency by sequentially measuring both enzymes from a single 
sample and eliminating the need for using -galactosidase for that purpose.   
HEK293T cells were co-transfected with the luciferase reporter vectors that either 
contained the putative E2F1 binding site insert, a mutated version of it or empty vector.  To 
directly explore regulation of zmpste24 expression by E2F1, cells were co-transfected with an 
E2F1 expression vector under the control of a CMV promoter (Invitrogen).   
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Figure 13: Reporter gene studies to test the putative E2F1 binding sites in the zmpste24 promoter. 
pGL4.27 [luc2P/minP] containing the wild type or mutated putative E2F1 response element and pGL4.77 
[hRenilla lucP] (transfection efficiency control) were co-transfected into HEK293T cells. Where indicated, 
cells were also co-transfected with a CMV-driven E2F1 expression vector. Figure shows a representative 
experiment out of four repetitions. Data is expressed as the average of triplicate luciferase 
measurements, normalized for protein, hRenilla luciferase and compared to transfection of empty 
pGL4.27 [luc2P/minP] vector. ** p<0.003 comparing between ERE and ERE + E2F1. 
 
Our results indicate that the promotor region in zmpSte24 contains a functioning E2F1 
response element that leads to an increased transcription of the luciferase reporter gene in 
HEK293T cells (Figure 13).  Of further interest, the putative E2F1 response element (ERE) was 
mutated, CCGGAAAAGGAACTCGG, this resulted in abolishment of expression of the reporter 
gene (Figure 13), including when cells were co-transfected with the E2F1 expression vector 
(Invitrogen).  Although these experiments suggest that E2F1 may indeed upregulate zmpste24 
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activity in vivo, further experiments using E2F1 null cells or similar, may be necessary to 
establish whether E2F1 modulates zmpste24 expression.   
Specific Prelamin A Interactions with Chromatin 
A variety of studies have shown a direct and indirect interaction between lamin A, lamin 
C, and chromatin, suggesting the possibility of a differential gene expression program between 
cells that are expressing or not expressing FC-prelamin A (Gruenbaum et al. 2000; Maraldi and 
Lattanzi 2005; Maraldi et al. 2006; Rusinol and Sinensky 2006).  The carboxyl terminal 
hydrophobic modifications of prelamin A localize it to the nuclear envelope (Hennekes and Nigg 
1994).  Lamin A has been shown to interact with various transcription factors as well as having 
more general binding interactions with chromatin (Goldman et al. 2005; Rzepecki et al. 2008; 
Piekarowicz et al. 2016).  Consequently, as lamin A interacts with chromatin to promote or to 
silence gene expression, prelamin A might be expected to act in similar manner.  However, the 
hydrophobic post-translational modification of prelamin A may also participate in bringing 
chromatin regions that interact with lamin A to the nuclear periphery where the new 
environment can affect gene expression.  Supporting this possibility, expression of progerin was 
shown to produce a loss of heterochromatin (Lowndes and Toh 2005; Walter et al. 2006; 
Rzepecki et al. 2008; Piekarowicz et al. 2016).  Additionally, a specific effect of prelamin A on 
heterochromatin sub-nuclear localization has been reported (Masny et al. 2004).  The 
possibility that such differential expression occurs has been supported by the effects of 
progerin on gene expression in HGPS fibroblasts.  A reported microarray analysis identified 
more than 60 differentially expressed genes in HGPS cells (Wang et al. 2006).  For example, 
ankyrin 3 mRNA is expressed more than 100-fold higher in HGPS fibroblasts compared to 
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normal human diploid fibroblasts.  However, the expression of ankyrin 3 at the protein level is 
similar between the HGPS and normal cells.  Additionally, some isoforms of ankyrin 3 have been 
reported to diminish fibroblast proliferation in response to the mitogen, PDGF, through 
inhibition of the PDGF receptor (Ignatiuk et al. 2006).  
Identification of prelamin A interacting proteins by proximity labeling  
In an attempt to isolate and identify proteins that specifically interact with Prelamin A, 
Progerin or Lamin A, we decided to use the recently developed methodology called "BioID" as 
an alternative to more common screening techniques for protein-protein interactions (Roux et 
al. 2012). In BioID, a modified E. coli biotin ligase (BirA*) is fused to a protein of interest. The 
biotin ligase fusion protein is then introduced into a live mammalian cell where it biotinylates 
vicinal proteins. Biotinylated proteins are then selectively isolated by binding to streptavidin 
linked to paramagnetic beads and identified by mass spectrometry.  
The main advantage of this method, is that the potential interacting partners are tagged 
in a natural cellular environment avoiding fixation, co-immunoprecipitation or other techniques 
that might lead to false positives. Furthermore, the nature of the tag (biotin) allows for 
extensive and convenient purification of the labeled proteins. Type A lamins, being members of 
the intermediate filament family, are relatively insoluble and therefore ideal candidates for 
BioID. 
Four cell lines were created as described in Materials and Methods using NEB’s 3T3 
Rheoswitch® cells as the background cell line. The cells expressed Biotin ligase (BL) or BL fusion 
proteins of GFP-Lamin A or GFP-L647R prelamin A, in a stable and inducible manner upon 
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incubation with GenoStat™ (Figure 14).  The fusion proteins showed the appropriate molecular 
weight as determined by SDS-PAGE followed by Western blot with anti-GFP antibodies. 
 
Expression and Sub-cellular Localization of Biotin Ligase-lamin Fusion Proteins 
Immunofluorescence of 3T3 Rheoswitch® BL-GFP-LA cells and 3T3 Rheoswitch®BL-GFP-
L647R-LA cells showed the sub-cellular localization of biotin ligase-lamin fusion proteins. In the 
3T3 Rheoswitch® BL-GFP-LA, the fusion proteins were in the expected location of the nuclear 
envelope similar to both endogenous lamin A and lamin A with a GFP tag (Bridges, 2011). In the 
3T3 Rheoswitch® BL-GFP-L647R-LA cells, the biotin ligase-lamin fusion protein localized to the 
nuclear lamina and also in nucleoplasmic aggregates (Figure 15).  
 
Figure 14: Expression of biotin ligase-lamins chimeras upon induction with GenoStat. 3T3 Rheoswitch 
cells harboring biotin ligase constructs were incubated for 48h with various concentrations of GenoStat. 
Cells were then lysed and total cell extracts were analyzed by SDS-PAGE and western blotting using anti-
GFP and Biotin Ligase antibodies. Rheo indicates untransfected cells. 
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Proximity labeling experiment 
The stable cell lines were used in the proximity labeling experiment as follows: 1-2 X 107 
cells were incubated for 24h in the presence of 500 µM GenoStat and 0 or 50µM biotin. Cells 
were then lysed under stringent conditions and biotinylated proteins were collected on 
streptavidin-conjugated beads (Dynabeads from Invitrogen) for subsequent analysis and 
identification by mass spectrometry. As a process intermediate control, aliquots of the eluted 
protein samples  were subjected to SDS-PAGE and probed for biotinylated proteins by western 
blotting with streptavidin linked to horse radish peroxidase (Figure 16). 
 
Figure 15: Co-localization of GFP-L647R-lamin A (green) and biotin ligase (red) fluorescence. 
Immunofluorescence was carried out with anti-GFP and anti-biotin ligase antibodies as described in 
Materials and methods.  
 
The following criteria was used for inclusion of the identified proteins as interacting 
partners: First, the average MASCOT (a software search engine that uses mass spectrometry 
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data to identify proteins from peptide sequence databases) score must be larger than 100. 
Second, the proteins must not be present (or be present with a 5-fold lower MASCOT score) in 
the no-biotin background control samples. Third, mitochondrial proteins (based on Gene 
ontology (GO) annotations) and keratins were intentionally excluded to focus on nuclear 
proteins.  In both cell lines the identified protein with the highest score was lamin A with an 
average MASCOT score of 3,123.  
 
Figure 16: Relative degree of biotinylation by BioID, BL-GFP-LA (LA) and BL-GFP-L647R-PreA (PreA). Cells 
were treated with 0, or 50 µM biotin for 48h. After cell lysis and isolation with streptavidin-linked 
Dynabeads, biotinylated proteins were eluted in Novex Li-sample buffer and analyzed by SDS-PAGE and 
western blotting with streptavidin-HRP. 
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Interacting partners were categorized as interactors of lamin A, interactors of L647R-
PreA or both. Many of the identified lamin A interactors were also detected in L647R-PreA 
samples and vice versa, requiring the use of additional criteria to identify differential 
interactors. Proteins were required to have a ratio of L647R-PreA over lamin A average 
MASCOT scores above 2.5 or below 0.25 in the samples from the respective cell lines. For 
example, Mascot scores were considered semi-quantitative only, and were used to distinguish 
proteins that might either have higher affinity for lamin A or L647R-PreA (or associated 
proteins) or were expressed more abundantly in BL-GFP-lamin A than in BL-GFP-L647R-cells. 
Whether these candidates bound lamins directly or indirectly cannot be revealed by this 
method.  
Lamin A and prelamin A vicinal proteins identified by proximity labeling.  
After applying the above described criteria to the data received from the proteomic core 
facilities, a total of 294 proteins were considered interactors of both L647R-PreA and lamin A 
(Table 1).   Sixteen proteins were considered preferential interactors of either L647R-PreA or 
lamin A cells; seven with L647R-PreA interactors and seven with Lamin A. Two proteins, PCNA 
and SCYE1, were also labeled that did not meet the selection criteria for exclusive PreA 
interactor, but were more strongly represented in the prelamin A cells samples.  Five out of the 
seven proteins in our screen that were biotinylated by BL-GFP-L647R-PreA were related to cell 
cycle control, in particular, regulation of processes involved in cell senescence. PIN1 and H2A.Z 
have been previously identified by our laboratory as prelamin A interactors. 
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Table 1: Differential interactors of BL-GFP-Lamin A or BL-GFP-L647RPreA. 
 
Proteins were sorted according to MASCOT score. Red, proteins detected only in uncleavable PreA 
samples according to the inclusion criterion. Orange, proteins detected in both samples (meet the 
inclusion criterion but there is a big difference in the preA samples. Green, proteins detected only in the 
lamin A samples according to inclusion criterion. 
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Pin1 was found to be a potential interactor by an in silico approach that was confirmed 
by co-immunoprecipitation (Bridges, 2011). In that study, Bridges showed that Pin1 was a 
primary mediator in PreA regulation of the cell cycle. Pin1 was shown to have binding sites in 
the PreA C-terminus, to directly bind preA in a phosphorylation dependent manner, and to be 
sequestered in the nucleus upon prelamin A accumulation. Pin1 has been implicated in the 
control of a multitude of cell cycle regulators (Lin et al. 2015), so it was speculated that 
sequestration by interaction with prelamin A may affect that process.  
 
Figure 17: Co-immunoprecipitation with lamin A or L647R prior to MALDI-TOF. Silver stained SDS-PAGE 
gel showing proteins co-immunoprecipitated with Lamin A or L647R-Prelamin A previous to band 
excision and analysis by MALDI-TOF. Proteins bands that were identified are labeled in the image. 
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Histone H2A.Z was more closely examined using an anti-prelamin A antibody developed 
by Sinensky et al. (Sinensky et al. 1994) and commercial anti-lamin A/C antibodies, which  
showed that H2A.Z is one of several proteins that co-immunoprecipitate with prelamin A. The 
experiment consisted of immunoprecipitation followed by MALDI-TOF identification as 
described in Materials and Methods (Figure 17).  
H2A.Z is interesting because it is one of the specialized histone variants that is deposited 
in nucleosomes independent of replication and is constitutively expressed in many cell types. 
Many lines of evidence strongly suggest H2A.Z might have a role in gene transcription. The best 
described role for H2A.Z in aging and senescence was shown by Gevry et al. 2007 and Lee et al. 
2012 They showed that depletion of H2A.Z by shRNA knockdown caused a p53-dependent 
increase in p21 expression resulting in premature senescence of WI-38 and IMR-90 human 
fibroblasts (Gevry et al. 2007) (Lee et al., 2012). 
One of the most striking findings of zmpste24 K.O. mice is the upregulation of p53 and 
p53 clients like p21, and GADD45g in skin fibroblasts and other tissues (Varela et al. 2005). 
Using a focused RT-PCR array, increases in p21, p27, FOXO3 and other regulators of the cell 
cycle in response to L647R prelamin A accumulation in Rheoswitch 3T3 cells were found in our 
lab. (Bridges, 2011).   
To determine whether the effect of uncleavable prelamin A on p21 expression levels 
might be mediated by H2A.Z a ChIP-PCR experiment was performed in which chromatin from 
Rheoswitch cells expressing L647R-PreA cells was isolated and immunoprecipitated with 
antibodies against H2A.Z. The purified genomic DNA was quantified by end-point PCR using 
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consensus primers specific for p21 (SABiosciences). Figure 18 shows that H2A.Z appears to be 
displaced from the p21 promoter region upon induction of L647R-PreA for 24h.  
 
Figure 18: H2A.Z is displaced from p21 promoter region upon expression of L647R Prelamin A. 
Chromatin immunoprecipitation (ChIP) was performed with anti-H2A.Z on chromatin preparations 
harvested from L647R Rheoswitch cells incubated in the presence or absence of 800nM Genostat for 
24h to induce the expression of uncleavable prelamin A. IgG represents non-specific background after 
immunoprecipitation with non-immune serum. The purified genomic DNA was quantified by end point 
PCR using consensus primers specific for p21 (SABiosciences). We used mouse GAPDN Internal 
Normalizer (SABiosciences) A) Representative separation of PCR products on agarose gel 
electrophoresis. B) Images were quantitated using G:Box image analysis system. Quantitation of 
Enrichment was determined as 100x (Ainput - Aenriched) after adjusting the percentage of input DNA used. 
Shown are average ± s.d. of three biological replicates. * = p<0.05. 
 
Next, changes in expression of p21 were measured in response to L647R-PreA 
accumulation. Transcription of the p21 gene was examined using a RT2 Endpoint PCR system 
from SABiosciences on RNA isolated from L647R or control cells incubated with different 
GenoStatTM concentrations for 24 h. PCR products were separated on 2% agarose.   
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Figure 19 shows that p21 transcripts increase with the GenoStat concentration in cells 
expressing L647R-PreA but not in untransfected cells (Rheo). 
 
Figure 19: CDKN1a (p21) expression changes upon induction of L647R-PreA. RNA was isolated from 
L647R-PreA Rheoswitch cells grown in the presence of various concentrations of GenoStat. First strand 
cDNA was synthesized and used in a RT2 endpoint PCR kit, using consensus primers for p21. PCR 
products were separated by electrophoresis in 2% agarose. We used mouse GAPDN Internal Normalizer 
(SABiosciences). 
 
Lastly, the effect of L647R-PreA accumulation on p21 protein levels was determined. 
Rheoswitch cells, L647R PreA or wild type Lamin A, (not shown) were induced with increasing 
concentrations of Genostat for 48 hours.  
Figure 20 shows that p21 levels parallel those of L647R-PreA upon induction with 
GenoStat.  
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Figure 20: p21 protein accumulation upon induction of L647R-PreA. 50 μg protein of total cell lysate 
per lane was separated by SDS PAGE on 4-12% gradient Bis Tris Gel and transferred to PVDF membrane, 
then the membrane was sequentially immunoblotted with anti-GFP antibody (Top Panel, equivalent to 
L647R-PreA), anti-p21 antibody and lamin B antibody (Bottom panel) after mild stripping of the 
membrane. 
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CHAPTER 4 
DISCUSSION 
Zmpste24 Structure/Function 
Since the 3.4 Å structure of zmpste24 was solved by Quigley et al., we contemplated 
possible explanations for the inhibition and covalent modification of zmpste24 by fluorescent 
serine-protease suicide inhibitors as determined by mass spectrometry. In the absence of a 
crystal structure for zmpste24, these results (Corrigan 2005) formed the basis and rational of 
our initial approach (to rescue zmpste24 KO cells with truncated forms of the enzyme) to study 
the structure-function relationship of zmpste24 and to test the “two site” hypothesis.  A 
possible explanation for the results that were observed is a non-specific inhibition 
(binding/covalent modification sterically alters the enzyme and affects the active site without 
actually binding to it) (Grabarek et al. 2002) and reviewed on (Grabarek and Darzynkiewicz 
2002). Regardless, the truncated forms that we developed could still be used for further studies 
of zmpste24 function (e.g. protein-protein interaction, activity regulation, etc.).    
Regulation of Zmpste24 Expression in Serum Starved Cells 
The results described above provide a justification for the hypothesis that prelamin A 
may serve a function in quiescence in response to mitogen withdrawal. This function could be 
to support the quiescent state directly or to help block the other possible cell fates that can 
occur under these conditions: apoptosis or necrosis. We have also presented evidence that 
prelamin A accumulation during serum starvation is mediated by down-regulation of zmpste24 
suggesting that the form of prelamin A that accumulates is the farnesylated and 
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carboxymethylated substrate of this enzyme. Consistent with this structural assignment, we 
utilized radiochemical methods to show that prelamin A that accumulates in serum starved BJ 
cells is prenylated (Figure 9), and carboxymethylated (Figure 9B). The relative 
carboxymethylation of prelamin A and lamin B, under these conditions is consistent with similar 
levels of CAAX-box processing. The predicted FC-prelamin A carboxyl terminal structure was 
confirmed by MALDI-TOF mass spectrometry (Figure 9A). Our promoter analysis experiments 
strongly suggest a mechanism of transcriptional regulation for zmpste24 levels in response to 
mitogen deprivation (Figure 21). Regulation seems to be mediated by the well-described Rb-E2F 
pathway. Under this condition, one mechanism may be that Rb is hypo-phosphorylated and 
binds to E2F1 transcription factor to inactivate it and in turn preventing upregulation zmpste24 
expression (Figure 21).  
 
Figure 21: Model of cell-cycle arrest by serum starvation.  Our hypothesis is that zmpSte24 is regulated 
by E2F resulting in changes FC-prelamin A accumulation which facilitates or prevents entry into and/or 
maintenance of G0.  
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It is likely that transcriptional regulation is not the only mechanism for zmpste24 down-
regulation since the zmpste24 mRNA levels decrease with slower kinetics (Figure 11) than the 
enzyme activity  in response to serum deprivation (Bridges, 2011). In our hands a 50% decrease 
in zmpste24 enzyme activity occurs in ~10 hours whereas the mRNA levels decline to 50% after 
16-32h. A potential explanation for this could be methodological or, more likely, a dual 
regulation where short-term enzyme inhibition can be accomplished by post-translational 
modification of zmpste24, perhaps by phosphorylation-de-phosphorylation and more 
persistent downregulation accomplished by modifying mRNA and/or protein turnover.  In 
support of this hypothesis, zmpste24 has been shown to be phosphorylated by aurora and 
polo-like kinases in mitotic cells. (Kettenbach et al. 2011). These kinases orchestrate almost 
every step of cell division, from entry into mitosis to cytokinesis. In a recent proteome-wide 
survey, other post-translational modifications identified in zmpste24 were five ubiquitination 
sites (residues 46, 66, 251, 314 and 437) which were speculated to participate in modulation of 
cell cycle progression by zmpste24 (Wagner et al. 2011).  
Using newer in silico detection algorithms (UCSC Genome Browser and the 
DECipherment Of DNA Elements database (DECODE), we have searched 20kb upstream and 
10kb downstream of zmpste24 and detected several other potential transcription factor 
binding sites.  Several members of the FOXO family have multiple putative binding sites in the 
5’ flanking region of the zmpste24 gene. This is particularly interesting since we have shown 
that FOXO3 is involved in the up-regulation of p27, a mediator in the quiescence related cell 
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cycle arrest, by transient expression of uncleavable prelamin A (Manuscript in preparation and 
Bridges, 2011).   
Another interesting result from our analysis of the zmpste24 gene promoter region is 
four binding sites for p53. Using commercially available primers for these sites in ChIP-PCR 
experiments using a ChIP certified p53 antibody (Qiagen), we have compared cells that are 
actively proliferating versus serum-starved quiescent WI38 cells.  Preliminary evidence shows 
slightly increased occupancy of three out of the 4 sites in the 5’ untranslated region of 
zmpste24 in quiescent cells. The physiological consequences of these findings are hard to 
predict, because outcomes of increased or decreased p53-mediated gene expression have been 
described in the literature (Riley et al. 2008; Tang et al. 2012).  
Identification of Prelamin A Interacting Proteins  
The isolation and identification of lamin proteins interacting partners has been hindered 
by the insoluble nature of lamin forms. In this study we have applied a recently developed in 
situ and in vivo biotin-tagging and isolation approach to identify lamin A and prelamin A lamin 
interactors. The procedure used is based on creating fusion proteins with a promiscuous Biotin 
Ligase and the protein of interest. It was developed by Roux et al. 2012 and was focused on 
isolation of lamin A interacting proteins (Roux et al., 2012). This method is an improved 
variation of a similar technique that involves expression of lamin A and progerin modified with 
the high-affinity OneSTrEP-tag, precipitation of lamin-protein complexes after reversible 
protein cross-linking and subsequent protein identification by mass spectrometry (Kubben et al. 
2010), a  study focused on identification of differential lamin A and progerin interacting 
proteins. Here we focused on proteins that preferentially “interact” with prelamin A. 
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Analysis of Table 1 shows that the majority of these proteins are related to chromatin 
organization or cell cycle control.  Of particular interest is H2A.Z. Under normal conditions 
H2A.Z seems to suppress the p53-dependent p21 transcription and senescence responses. 
H2A.Z is placed within the p21 promoter, by the p400 ATPase chromatin repressing p21 gene 
expression. Both, downregulation of p400 or siRNA knockdown of H2A.Z lead to p53/p21 
senescence responses (Gévry et al. 2007; Lee et al. 2012). Our laboratory has previously shown 
that persistent expression of uncleavable prelamin A in 3T3 Rheoswitch cells led to a 
progressive accumulation of β-galactosidase in positive cells, a hallmark of the senescent state 
(Figure 22). 
   
Figure 22: Cell senescence upon persistent L647RPreA expression. L647R PreA Rheoswitch cells, 
Induced for expression (500nM GenoStat, red bars) or Uninduced (blue bars) were split every other day 
in 1:3 ratio. At the indicated passage number, senescence was measured with a β -galactosidase staining 
kit. (Adapted from Bridges, 2011). 
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Therefore, a possible mechanism for the up-regulation of p21 seen in Figures 20 and 21 
is by epigenetic displacement or sequestration of H2A.Z by prelamin A from promoter regions 
where H2A.Z exerts an inhibitory role on transcription.  In conclusion, the association of H2A.Z 
with the accumulated L647R prelamin A could provide and epigenetic mechanism for the 
senescence phenotype observed in these cells. 
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